GlassScriptPhysician profile
Constantine Stavrinoudis
NPI 1063813343
$1,481.77
in general payments reported to CMS, 2019-2025
10 companies · $35.42 in 2025
The $35.42 reported for 2025 was less than what a typical Prosthodontics provider received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.49 · 2021: $256 · 2022: $151 · 2023: $774 · 2024: $225 · 2025: $35.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Entertainment: $850 · Food and Beverage: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Entertainment | $850.10 |
| Food and Beverage | $184.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Keystone Dental INC. | $850.10 | 2023-2024 | |
| Nobel Biocare USA | $203.04 | 2019-2023 | Nobelactive |
| Neoss, INC. | $116.91 | 2021 | |
| Straumann USA LLC | $99.71 | 2022-2024 | |
| Align Technology, INC. | $55.70 | 2021 | |
| Biohorizons Implant Systems INC. | $52.17 | 2022 | |
| Dentsply Sirona INC | $35.42 | 2025 | Steri-Mate, Tph Spectra Universal Composite Restorative Low Viscosity |
| Envista Holdings Corporation | $27.92 | 2024 | Maxcem Elite |
| Geistlich Pharma, North America, INC. | $23.99 | 2022 | |
| Orapharma, A Division of Bausch Health US, LLC | $16.81 | 2024 | Arestin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constantine Stavrinoudis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.